At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 134 enrolled
Drug / intervention
lenalidomidedrug
Likely dose
lenalidomide 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety Of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantel Cell NHL Who Have Relapsed Or Progressed After Treatment With Bortezomib Or Are Refractory To Bortezomib
In Brief
A Phase 2 clinical trial evaluating lenalidomide for Mantle Cell Lymphoma. Completed, enrolled 134 participants across 70 sites in 14 countries.
Detailed Summary
To evaluate the safety and efficacy of Lenalidomide (Revlimid (R)) in subjects with mantle cell lymphoma who have relapsed, progressed or are refractory to bortezomib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMantle Cell Lymphoma
CountriesAustria, Belgium, Colombia, France, Germany, Hungary, Israel, Italy, Puerto Rico, Singapore, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartDec 2008
Primary CompletionApr 2016
Study CompletionNov 2017
TodayJul 2026
First PostedAug 19, 2008
Enrollment StartDec 22, 2008
Primary CompletionApr 6, 2016
Study CompletionNov 8, 2017
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 17.9 years ago
Interventions
lenalidomidedrug
25mg oral capsules continuous days 1-21 each of a 28 day cycle